Diabetes drug shows promise for kidney and heart health in Non-Diabetic patients
NCT ID NCT07344922
First seen Jan 19, 2026 · Last updated Jun 17, 2026 · Updated 19 times
Summary
This study tested whether dapagliflozin, a drug typically used for diabetes, can slow kidney decline, improve anemia, and support heart health in 100 adults with chronic kidney disease who do not have diabetes. Participants took either the drug or a placebo daily for 12 months alongside their usual care. The goal is to find a new way to manage these conditions without relying on lifelong medications beyond the study period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Urology and Nephrology Center, Mansoura University
Al Mansurah, Dakahlia Governorate, 35511, Egypt
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.